AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine
September 04 2019 - 8:00AM
Business Wire
- Somatic restriction theory of aging unifies numerous aspects of
aging, regeneration and cancer biology
- Highlights significance of AgeX’s induced Tissue Regeneration
(iTRTM) technology for development of advanced therapies for aging
and cancer
- AgeX has formed Reverse Bioengineering, Inc. to develop and
commercialize iTR technology
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on therapeutics for human aging and
regeneration, announced today that founder and CEO Michael D. West,
Ph.D., and colleagues have authored a paper in the peer-reviewed
scientific journal Regenerative Medicine on the theoretical
foundation of the Company’s induced Tissue Regeneration (iTRTM)
technology. The paper presents the work of the company’s scientists
in describing a unified theory of aging and regeneration that could
pave the way for the development of new therapies for a variety of
age-related degenerative diseases and conditions.
“The longevity sector is advancing at an accelerating pace, but
for the most part, without a consensus on the fundamental root
causes of aging,” commented Dr. West. “We believe that it is now
possible to collate the diverse observations about aging into a
unified model. In the paper titled, ‘Toward a Unified Theory of
Aging and Regeneration’ we outline such a theory that underlies the
technological underpinnings of the company’s induced tissue
regeneration (iTR) program.”
The paper explores the mechanisms of aging and shares important
insights into molecular biology of cell aging and immortalization,
as well as the mechanisms of cell age reversal by somatic cell
nuclear transfer and transcriptional reprogramming. Lastly, the
paper explores the prospects of cell age reversal in vivo, that is
in the patient, as opposed to in vitro (the laboratory dish).
“We are fortunate to have at AgeX some of the first scientists
in the world to envision applying reprogramming technology to the
problems of aging,” commented Greg Bailey, M.D., Chairman of the
Board of Directors. “Our ultimate aim is to not only lead in the
basic research in this new field, but to also lead in the
translation of the science into safe and effective therapeutics for
the aging population. To accomplish the latter goal, we have
incorporated a new subsidiary of AgeX, Reverse Bioengineering, Inc.
with the primary mission of advancing this emerging
technology.”
Co-authors on the paper are Hal Sternberg, PhD, Ivan Labat, PhD,
Jeffrey Janus, Karen B. Chapman, PhD, Nafees N. Malik, MD, Aubrey
D.N.J. de Grey, PhD, and Dana Larocca, PhD.
A video summarizing the technology described in the paper is
available for viewing online. The paper was published online ahead
of print on Wednesday, August 28, 2019. It may be found here.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan,
and is seeking opportunities to form licensing and partnership
agreements around its broad IP estate and proprietary technology
platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in AgeX’s reports filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. AgeX specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190904005371/en/
Media Contact for AgeX:
Bill Douglass Gotham Communications, LLC bill@gothamcomm.com
(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Sep 2023 to Sep 2024